Portal vein thrombosis related to Cassia angustifolia

Clinical Toxicology

Volumn 46, Issue 8, 2008, Pages 774-777

  Soyuncu, Secgin ^a   Cete, Yildiray ^a   Nokay, Ali E ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Herbal; Portal vein thrombosis; Toxicology

Indexed keywords

ENOXAPARIN; HERBACEOUS AGENT; WARFARIN;

ABDOMINAL TENDERNESS; ADULT; ANOREXIA; ARTICLE; BLEEDING; CASE REPORT; CASSIA ANGUSTIFOLIA; COLOR ULTRASOUND FLOWMETRY; ELECTROPHORESIS; EPIGASTRIC PAIN; FEMALE; FEVER; FIBRINOLYTIC THERAPY; HUMAN; PLANT LEAF; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; SENNA; VEIN BLOOD FLOW; VOMITING;

ADULT; ANTICOAGULANTS; FEMALE; HUMANS; LAXATIVES; PLANT EXTRACTS; PLANT LEAVES; PORTAL VEIN; SENNA PLANT; THROMBOLYTIC THERAPY; TREATMENT FAILURE; ULTRASONOGRAPHY, DOPPLER, COLOR; VENOUS THROMBOSIS;

FABACEAE; SENNA; SENNA ALEXANDRINA;

EID: 52449129229     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701682097     Document Type: Article

References (48)

1. Leng-Peschlow E. The importance of senna products. Pharmacol 1992; 44(suppl. 1):1-2.
2. Heaton KW, Cripps HA. Straining at stool and laxative taking in an English population. Dig Dis Sci 1993; 38(6):1004-8.
3. Lemli J. Metabolism of sennosides - an overview. Pharmacol 1988; 36(suppl. 1):126-128.
4. Chevallier A. Encyclopedia of Medicinal Plants. New York: DK Publishing, 1996:72.
5. Newall C, Anderson LA, Phillipson JD. Herbal Medicines. London: Pharmaceutical Press, 1996:243-44.
6. Bisset N. Herbal Drugs and Phytopharmaceuticals. Stuttgart, Germany: CRC Press Inc., 1994:463-66.
7. Van der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993:329:1073-8.
8. Van Hoestenberghe A, De Witte P, Geboes K, Eyssen H, Nijs G, Lemli J. The effect of rhein and rhein anthrone on intestinal fluid transport and on large intestine transit in germ free rats. Eur J Pharmacol 1992:212: 121-3.
9. Van Gorkom BA, De Vries EG, Karrenbeld A, Kleibeuker JH. Review article: Anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther. 1999r; 13(4):443-52.
10. Blumenthal M, Brinckmann J, Goldberg A, eds. Herbal Medicine: Expanded Commission E Monographs. Newton, MA: Integrative Medicine Communications, 2000.
11. Spiller HA, Winter ML, Weber JA, Krenzelok EP, Anderson DL, Ryan ML. Skin breakdown and blisters from senna-containing laxatives in young children. Ann Pharmacother. 2003; 37(5):636-9.
12. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Safety 1994; 10(1):47-65.
13. Faber P, Strenge-Hesse A. Senna-containing laxatives: Excretion in the breast milk? Geburtshilfe Frauenheilkd 1989; 49(11):958-62.
14. American Academy of Pediatrics. The transfer of drugs and other chemicals in to human milk. Accessed 15 June, 2007, at http://aappolicy.aappublications. org/cgi/content/full/pediatrics;108/3/776#T6, 2005
15. Mengs U. Reproductive toxicological investigations with sennosides. Arzneimittelforschung. 1986; 36:1355-8.
16. Faber P, Strenge-Hesse A. Relevance of rhein excretion into breast milk. Pharmacol 1988; 36(suppl. 1):212-20.
17. Roberts, NL. CMT Pharmacology 101. Journal of the American Association for Medical Transcription 2005; 24(1):31-33.
18. U.S. Food and Drug Administration. Accessed 15 June, 2007, at http://www.fda.gov/OHRMS/DOCKETS/dailys/03/Aug03/081503/78n-0036l-bkg0004-08- tab10-vol1.pdf
19. Blumenthal M, Busse WR, Goldberg A, Gruenwald, J, Hall T, Riggins CW, Rister RS, eds. The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998:204-8.
20. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007; 39(4):293-304.
21. Sonmez A, Yilmaz MI, Mas R, Ozcan A, Celasun B, Dogru T, Taslipinar A, Kocar IH. Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation. Acta Gastroenterol Belg 2005; 68(3):385-7.
22. Stickel F, Seitz HK, Hahn EG, Schuppan D. Liver toxicity of drugs of plant origin. Z Gastroenterol 2001; 39(3):225-32, 234-7.
23. Webster GJ, Burroughs AK, Riordan SM. Review article: portal vein thrombosis-new insights into aetiology and management. Aliment Pharmacol Ther 2005; 21(1):1-9.
24. Pati J, Srivastava M, Sahni P. Extra hepatic portal vein thrombosis in a child associated with lupus anticoagulant. J Trop Pediatr 2003; 49:191-2.
25. Hirohato Y, Murata A, Abe S, Otsuki M. Portal vein thrombosis associated with antiphospholipid syndrome. J Gastroenterol 2001; 36:574-8.
26. Brady L, Magilavy D, Black D. Portal vein thrombosis associated with antiphospholipid antibodies in a child. J Pediatr Gastroenterol Nutr 1996; 23:470-3.
27. Arav-Boger R, Reif S, Bujanover Y. Portal vein thrombosis caused by protein C and protein S deficiency associated with cytomegalovirus infection. J Pediatr 1995; 126:586-8.
28. Seixas C, Hessel G, Ribeiro C, Arruda V, Annichino-Bizzacchi J. Factor V Leiden is not common in children with portal vein thrombosis. Thromb Haemost 1997; 77:258-61.
29. Seixas C, Hessel G, Siqueira L, Machada T, Gallisoni A, Annichino-Bizzacchi J. Study of hemostasis in pediatric patients with portal vein thrombosis. Haematologica 1998; 83:946-60.
30. Ahuja V, Marwaha N, Chawla Y, Dilawari J. Coagulation abnormalities in idiopathic portal vein thrombosis. J Gastroenterol Hepatol 1999; 14:1210-1.
31. Janssen HLA, Wijnhoud A, Haagsma EB, van Uum M, van Nieuwkerk CMJ, Adang RP, Chamuleau RAFM, Van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, Van Hoek B. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49:720-4.
32. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31:587-91.
33. Vanderperren B, Rizzo M, Angenot L, Haufroid V, Jadoul M, Hantson P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother 2005; 39(7-8):1353-7.
34. Beuers U, Spengler U, Pape G. Hepatitis after chronic abuse of senna. Lancet 1991; 337:372-3.
35. Westendorf J, Marquardt B, Poginski M, Dominiak J, Schmidt H, Marquardt H. Genotoxicity of naturally occurring hydroxyanthraquinones. Mutat Res 1990; 240:1-12.
36. Heidemann A, Miltenburger HG, Mengs U. The genotoxicity status of senna. Pharmacol 1993; 47(Suppl 1):178-186.
37. Siegers CP. Anthranoid laxatives and colorectal cancer. Trends Pharmacol Sci 1992; 13:229-231.
38. Westendorf J. Pharmakologische und toxikologische Bewertung von Anthranoiden. Pharm Z 1993; 138:3891-3902.
39. Kune GA. Laxative use not a risk for colorectal cancer: data from the melbourne colorectal cancer study. Z Gastroenterol 1993; 31:140-143.
40. Nusko G, Schneider B, Müller G, Kusche J, Hahn EG. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma. Pharamcol 1993; 47(suppl. 1):234-241.
41. Lyden-Sokolowski A, Nilsson A, Sjoberg P. Two-year carcinogenicity study with sennosides in the rat: Emphasis on gastro-intestinal alterations. Pharmacol 1993; 47(suppl. 1):209-215.
42. Prandoni P. Acquired risk factors of venous thromboembolism in medical patients. Pathophysiol Haemost Thromb 2006; 35(1-2):128-32.
43. Mammen EF. Pathogenesis of venous thrombosis. Chest 1992; 102(6 suppl.):640S-644S.
44. Hidajat N, Stobbe H, Griesshaber V, Felix R, Schroder RJ. Imaging and radiological interventions of portal vein thrombosis. Acta Radiol 2005; 46(4):336-43.
45. Hidajat N, Stobbe H, Griesshaber V, Schroder RJ, Felix R. Portal vein thrombosis: Etiology, diagnostic strategy, therapy and management. Vasa 2005; 34(2):81-92.
46. Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Kontetsu S, Hori N, Watanabe T, Nagawa H, Omata M. Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation. J Gastroenterol Hepatol 2001; 16:1429-33.
47. Condat B, Pessione F, Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalisation on anticoagulant therapy. Hepatology 2000; 32:466-70.
48. Condat B, Pessione F, Hillaire S, Denninger M, Guillin M, Poliquin M, Hadengue A, Erlinger S, Valla D. Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy. Gastroenterology. 2001; 120:490-7.